Estimated Veterans Health Administration costs for Alzheimer’s disease treatment with aducanumab-Reference-Cited by-同舟云学术

Estimated Veterans Health Administration costs for Alzheimer’s disease treatment with aducanumab

Published:2021-07-30 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Haimovich Adrian D.^ORCID,Goulet Joseph L.^ORCID,Brandt Cynthia A.^ORCID,Tarabar Asim,Patwa Huned S,Hwang Ula^ORCID

Abstract

AbstractThe approval of aducanumab for the treatment of Alzheimer’s disease has been met with significant public concern. Projections of annual cost across United States Medicare beneficiaries are in the tens of billions of dollars. Here, we performed an electronic health record review of Veterans Affairs beneficiaries, identifying 151,921 individuals (1.7%) with diagnosis codes for Alzheimer’s disease. We estimate that treatment for this cohort will cost in excess of $4 billion annually with further expenditures for associated screening, consultations, imaging, and therapeutic monitoring. The magnitude of projected expenditures necessitates early assessment of drug cost effectiveness.

Publisher

Cold Spring Harbor Laboratory

Reference6 articles.

1. Office of the Commissioner. FDA Grants Accelerated Approval for Alzheimer’s Drug. Published July 6, 2021. Accessed June 25, 2021. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-drug

2. Cubanski J , Neuman T. FDA’s Approval of Biogen’s New Alzheimer’s Drug Has Huge Cost Implications for Medicare and Beneficiaries. Published June 10, 2021. Accessed June 25, 2021. https://www.kff.org/medicare/issue-brief/fdas-approval-of-biogens-new-alzheimers-drug-has-huge-cost-implications-for-medicare-and-beneficiaries/

3. Severity Distribution of Alzheimer’s Disease Dementia and Mild Cognitive Impairment in the Framingham Heart Study;J Alzheimers Dis,2021

4. Department of Veterans Affairs. FY 2022 Budget Submission: Medical Programs and Information Technology Programs. 2022 Congressional Submission, Volume II. Accessed July 9, 2022. https://www.va.gov/budget/docs/summary/fy2022VAbudgetVolumeIImedicalProgramsAndInformationTechnology.pdf

5. Aducanumab Label. Published 6/2021. Accessed June 25, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761178s000lbl.pdf